ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Primary Endpoint Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study: Nanvuranlat, LAT1 Inhibitor for Patients With Pretreated Advanced Refractory BTC
By
ASCO GI 2023 Conference Coverage
FEATURING
Junji Furuse
By
ASCO GI 2023 Conference Coverage
FEATURING
Junji Furuse
56 views
February 23, 2023
Comments 0
Login to view comments.
Click here to Login
Videos